Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
26.15
-2.34 (-8.21%)
Sep 10, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $38.75. The average 1-year stock price forecast is 48.18% higher than the current stock price, while the lowest is $23 (-12.05%) and the highest is $47 (+79.73%).
Price Target: $38.75 (+48.18%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 10 | 10 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $45 | Buy | Maintains | $45 | +72.08% | Sep 10, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $35 → $40 | Buy | Reiterates | $35 → $40 | +52.96% | Sep 8, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Reiterates $29 | Hold | Reiterates | $29 | +10.90% | Aug 11, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $22 → $23 | Hold | Reiterates | $22 → $23 | -12.05% | Aug 10, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $34 → $42 | Buy | Reiterates | $34 → $42 | +60.61% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
78.61M
from 247.00M
Decreased by -68.17%
Revenue Next Year
52.08M
from 78.61M
Decreased by -33.75%
EPS This Year
-3.53
from -3.29
EPS Next Year
-3.34
from -3.53
EPS and Forward PE are based on non-GAAP adjusted numbers.